摘要
目的 观察吉西他滨联合卡铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法 41例晚期非小细胞肺癌患者给予吉西他滨与卡铂联合治疗 ,吉西他滨 10 0 0mg/m2 ,静脉滴注第 1、8、15天 ,卡铂AUC 5 ,静脉滴注第 1天 ,2 8天为一周期 ,每例患者治疗 2周期以上。结果 全组完全缓解 2例 ,部分缓解 18例 ,稳定15例 ,进展 6例 ,总有效率为 48.8%。初治组有效率为 5 5 .6% ,复治组为 43 .5 % (P >0 .0 5 )。全组中位生存期 11.8月 ,1年生存率为 49%。KPS评分增加者占 70 .7% ( 2 9/4 1)。最常见的毒副反应为骨髓抑制 ,Ⅲ～Ⅳ度白细胞和血小板下降发生率分别为 3 4.1%和 2 9.3 % ,其余毒副反应均轻微 ,可耐受。结论 吉西他滨联合卡铂一线治疗或二线治疗晚期非小细胞肺癌均有较好的疗效 ,毒性可以耐受。
Objective To evaluate the efficacy and toxicity of the combination of gemcitabine and carboplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods Forty-one patients with locally advanced (stage ⅢB) or metastatic (stage Ⅳ) NSCLC were enrolled into the study. The patients received gemcitabine 1 000 mg/m 2 on days l, 8 and 15, and carboplatin AUC 5 on day 1, with 28 days as a cycle. Each patient received at least two cycles. Results Of the 41 patients, 2 cases got complete response, 18 got partial response, 15 had stable disease, and 6 had progressive disease, with an overall response rate of 48.8%. The response rate was 55.6% (10/18) in the initial patients, and 43.5% (10/23) in the retreated patients (P>0.05). The median survival duration was 11.8 months. The 1-year survival rate was 49%. There were 29 patients whose KPS score increased. The main toxicities were leukopenia (incidence of 34.1% for grade Ⅲ+Ⅳ) and thrombocytopenia (incidence of 29.3% for grade Ⅲ+Ⅳ). Conclusion The combination of gemcitabine and carboplatin is a feasible, well-tolerated and active scheme in either first-line or second-line treatment of advanced NSCLC.
出处
《中国肺癌杂志》
CAS
2004年第2期168-170,共3页
Chinese Journal of Lung Cancer
